Prodotti GS / Area Oncology
Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial
![Immagine News](/media/0icnkhat/cat-1.jpg?center=0.55476190476190479,0.25&mode=crop&width=722&height=442)
Pembrolizumab monotherapy showed antitumour activity and manageable toxicity in patients with BCG-unresponsive high-risk Ta or T1 bladder cancer without carcinoma in situ and could potentially be a suitable treatment option for patients who decline or are ineligible for radical cystectomy. Findings will need to be confirmed in a randomised controlled trial.
Full article @ Lancet here
Grazie per il tuo feedback!